Corcept Therapeutics

Corcept Therapeutics company information, Employees & Contact Information

We’ve been unlocking the potential of cortisol modulation for more than 25 years. We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.

Company Details

Employees
634
Founded
-
Address
101 Redwood Shores Pkwy, Redwood City,california 94065,united States
Phone
16503273218
Email
in****@****ept.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Redwood City, California
Looking for a particular Corcept Therapeutics employee's phone or email?

Corcept Therapeutics Questions

News

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment - Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment Business Wire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call Yahoo Finance

Corcept Earnings: Record Patient Growth Drives 19% Revenue Jump, Pipeline Scores Multiple Wins - Stock Titan

Corcept Earnings: Record Patient Growth Drives 19% Revenue Jump, Pipeline Scores Multiple Wins Stock Titan

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Yahoo Finance

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care Yahoo Finance

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 - Business Wire

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 Business Wire

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension - Yahoo Finance

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension Yahoo Finance

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Business Wire

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Business Wire

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - Business Wire

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting Business Wire

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer Business Wire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update - Business Wire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update Business Wire

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism - Yahoo Finance

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism Yahoo Finance

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) Business Wire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Yahoo Finance

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Yahoo Finance

Court Finds Corcept Therapeutics’ Patents Not Infringed - Stock Titan

Court Finds Corcept Therapeutics’ Patents Not Infringed Stock Titan

Corcept Therapeutics Announces Fourth Quarter and Full-Year - GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year GlobeNewswire

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant - GlobeNewswire

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant GlobeNewswire

Corcept Therapeutics Announces Allowance of Additional - GlobeNewswire

Corcept Therapeutics Announces Allowance of Additional GlobeNewswire

Top Corcept Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant